Sensei Biotherapeutics (NASDAQ:FTH) Stock Bumped Down to "Sell" by Wall Street Zen

Key Points

• Wall Street Zen downgraded Sensei Biotherapeutics to “Sell” from “Hold,” contrasting with the broader analyst consensus of “Moderate Buy” and an average price target of $56.25.
• FTH opened at $28.00, with a market capitalization of approximately $723.5 million and a 52-week trading range of $7.45 to $42.14. The company reported quarterly EPS of -$2.84, beating estimates of -$5.04.
• Insiders purchased 13,634 shares worth about $326,118 over the past 90 days, while institutional investors and hedge funds own approximately 10.5% of the stock.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other research firms have also recently commented on FTH. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They set an "outperform" rating and a $51.00 target price for the company. Oppenheimer started coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They issued an "outperform" rating and a $60.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price target on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Needham & Company LLC initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They set a "buy" rating and a $56.00 price objective on the stock. Finally, Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They set an "outperform" rating and a $57.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $56.25.

Sensei Biotherapeutics Stock Performance

NASDAQ:FTH opened at $28.00 on Friday. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14. The stock has a 50-day simple moving average of $32.07. The firm has a market capitalization of $723.52 million, a PE ratio of -0.20 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts' consensus estimates of ($5.04) by $2.20. As a group, equities research analysts expect that Sensei Biotherapeutics will post -13.69 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Brian C. Stephenson bought 7,803 shares of Sensei Biotherapeutics stock in a transaction on Tuesday, June 30th. The shares were bought at an average price of $24.25 per share, with a total value of $189,222.75. Following the acquisition, the chief financial officer directly owned 41,688 shares in the company, valued at approximately $1,010,934. This represents a 23.03% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders purchased 13,634 shares of company stock worth $326,118. Company insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC bought a new position in Sensei Biotherapeutics during the second quarter worth $307,000. Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics during the second quarter worth $3,610,000. Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics in the 1st quarter worth about $22,758,000. Bank of America Corp DE lifted its position in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after buying an additional 32,719 shares during the last quarter. Finally, Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company's research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei's technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.